Affordable Access

deepdyve-link
Publisher Website

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Authors
  • Mu, Zhuan-Zhuan1, 2
  • Zhang, Xin1, 2
  • Lin, Yan-Song1, 2
  • 1 Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing, China. , (China)
  • 2 Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China. , (China)
Type
Published Article
Journal
Chonnam medical journal
Publication Date
Sep 01, 2019
Volume
55
Issue
3
Pages
127–135
Identifiers
DOI: 10.4068/cmj.2019.55.3.127
PMID: 31598469
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Most differentiated thyroid cancer (DTC) patients have an excellent prognosis. However, about one-third of DTC patients with recurrent or metastatic disease lose the hallmark of specific iodine uptake initially or gradually and acquire radioactive iodine-refractory DTC (RAIR-DTC) with poor prognosis. Due to the potentially severe complications from unnecessarily repeated RAI therapy and encouraging progress of multiple targeted drugs for advanced RAIR-DTC patients, it has become crucial to identify RAIR-DTC early. In this review, we focus on the progress and controversies regarding the defining of RAIR-DTC, further with subsistent approaches and promising molecular nuclear medicine imaging in identifying RAIR-DTC, which may shed light on the proper management methodsof such patients. © Chonnam Medical Journal, 2019.

Report this publication

Statistics

Seen <100 times